This article is more than 5 years old. Information may no longer be current.
MacuHealth, M&S Technologies partner to advance care
Click Here to Manage Email Alerts
MacuHealth and M&S Technologies have announced a partnership to educate eye care professionals on the benefit of enriching macular pigment with nutritional supplements.
Through the partnership, the companies will launch cooperative programs to promote M&S contrast sensitivity technology and MacuHealth’s LMZ3 formula, according to a press release from MacuHealth.
“There is now level 1 scientific evidence that demonstrates a direct correlation between rebuilding and enriching macular pigment with MacuHealth's triple carotenoid formulation in patients with healthy eyes (with best corrected Snellen visual acuity) and patients with macular disease (such as age-related macular degeneration and diabetic retinopathy) with improved contrast sensitivity,” Frederic Jouhet, founder and managing director of MacuHealth, said in the release. “We now know with 100% confidence that enriching macular pigment with MacuHealth with LMZ3 will improve visual performance (contrast), even when the patient has what is normally considered perfect vision.”
M&S has developed a letter contrast sensitivity protocol that allows eye care professionals to determine true visual performance.